Leukemia, Myelocytic, Acute Clinical Trial
Official title:
Anti-Leukemic Dendritic Cell Activated Donor Lymphocytes for Therapy of Relapsed Leukemia After Allogeneic Stem Cell Therapy
Objectives:
1. Determine the toxicity of infusions of allogeneic donor lymphocytes activated by acute
leukemia derived dendritic cells (DC/ADL) in relapsed patients after allo-stem cell
transplants.
2. Quantitate the alloreactivity of DC/ADL and circulating immune effector cells in
patients after infusion.
3. Assess efficacy of acute myelogenous leukemia (AML) or Chronic Myelogenous Leukemia in
Blastic Crisis (CML-BC) derived dendritic cells and activated lymphocytes in promoting
and sustaining remission in patients with relapse after allo-BMT or stem cell
transplant.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT00393380 -
Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor
|
Phase 2 | |
| Completed |
NCT01716793 -
Risk-adapted Therapy for Adult Acute Myeloid Leukemia.
|
Phase 2 | |
| Terminated |
NCT00152594 -
Voriconazole or Placebo in the Prophylaxis of Lung Infiltrates in Patients Undergoing Induction Chemotherapy for Acute Myelogenous Leukemia
|
Phase 3 | |
| Completed |
NCT01723657 -
Risk Adapted Treatment for Primary Acute Myeloid Leukemia (AML)
|
Phase 2 | |
| Recruiting |
NCT01034592 -
Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent Anemia
|
N/A | |
| Completed |
NCT00406393 -
Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402)
|
Phase 3 | |
| Recruiting |
NCT00126321 -
Cladribine, Cytarabine and Idarubicin in Patients With Relapsed Acute Myelocytic Leukemia (AML)
|
Phase 2 | |
| Recruiting |
NCT00449319 -
AML Treatment in Untreated Adult Patients
|
N/A | |
| Completed |
NCT00186381 -
Autologous Bone Marrow Transplantation in Acute Non-Lymphoblastic Leukemia During First or Subsequent Remission
|
Phase 2 | |
| Completed |
NCT00962767 -
Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular Remission
|
Phase 3 | |
| Completed |
NCT01756118 -
A Phase I, Dose-finding Study of BEZ235 in Adult Patients With Relapsed or Refractory Acute Leukemia
|
Phase 1 | |
| Terminated |
NCT01339910 -
Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)
|
Phase 3 | |
| Completed |
NCT00201240 -
Acute Myeloid Leukemia T Cell Depletion to Improve Transplants in Adults With Acute Myeloid Leukemia (BMT CTN 0303)
|
Phase 2 | |
| Terminated |
NCT01050946 -
Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related Donor and One Umbilical Cord Unit
|
Phase 2 | |
| Terminated |
NCT00446303 -
A Phase II Study of Maintenance With Azacitidine in MDS Patients
|
Phase 2 | |
| Completed |
NCT00044486 -
Prophylaxis Trial of Posaconazole Versus Standard Azole Therapy for Neutropenic Patients (Study P01899)
|
Phase 3 | |
| Active, not recruiting |
NCT02158858 -
A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis
|
Phase 1/Phase 2 | |
| Completed |
NCT00286845 -
Use of the MiCK Assay for Apoptosis in AML
|
Phase 1 | |
| Completed |
NCT00251368 -
Multicenter Study of 9-Aminocamptothecin (9-AC) in Patients With Refractory Leukemia
|
Phase 1 | |
| Recruiting |
NCT02895412 -
Infection and Tumour Antigen Cellular Therapy
|
Phase 1 |